Intratumoral CD16± Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

被引：14

作者：

Lee, Hansol ^{[1
,2
,3
]}

Ferguson, Angela L. ^{[2
,3
,4
,5
]}

Quek, Camelia ^{[1
,2
,3
]}

Vergara, Ismael A. ^{[1
,2
,3
]}

daSilva, Ines Pires ^{[1
,2
,3
,6
]}

Allen, Ruth ^{[2
,3
]}

Gide, Tuba Nur ^{[1
,2
,3
]}

Conway, Jordan W. ^{[1
,2
,3
]}

Koufariotis, Lambros T. ^{[7
]}

Hayward, Nicholas K. ^{[7
]}

Waddell, Nicola ^{[7
]}

Carlino, Matteo S. ^{[1
,8
]}

Menzies, Alexander M. ^{[1
,2
,8
,9
]}

Saw, Robyn P. M. ^{[1
,2
,9
,10
]}

Shklovskaya, Elena ^{[1
,11
]}

Rizos, Helen ^{[1
,11
]}

Lo, Serigne ^{[1
,2
]}

Scolyer, Richard A. ^{[1
,2
,3
,10
,12
]}

V. Long, Georgina ^{[1
,2
,3
,8
,9
]}

Palendira, Umaimaintha ^{[1
,2
,3
,4
,5
]}

Wilmott, James S. ^{[1
,2
,3
,13
]}

机构：

[1] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[2] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia

[3] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia

[4] Univ Sydney, Centenary Inst, Sydney, NSW, Australia

[5] Univ Sydney, Charles Perkins Ctr, Sch Med Sci, Infect Immun & Inflammat Theme, Sydney, NSW, Australia

[6] Westmead & Blacktown Hosp, Sydney, NSW, Australia

[7] QIMR Berghofer Med Res Inst, Herston, Qld, Australia

[8] Royal North Shore Hosp, Sydney, NSW, Australia

[9] Mater Hosp, North Sydney, NSW, Australia

[10] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[11] Macquarie Univ, Fac Med Hlth & Human Sci, Sydney, NSW, Australia

[12] NSW Hlth Pathol, Sydney, NSW, Australia

[13] Univ Sydney, Charles Perkins Ctr, Cent Clin Sch, Sydney, NSW 2037, Australia

来源：

CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 13期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

TUMOR-ASSOCIATED MACROPHAGES; CELL-MEDIATED CYTOTOXICITY; MONOCLONAL-ANTIBODY; T-CELLS; DEPENDENT CYTOTOXICITY; B-CELLS; RITUXIMAB; COMPLEMENT; EXPRESSION; CD16;

D O I：

10.1158/1078-0432.CCR-22-2657

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: This study characterizes intratumoral macrophage populations within baseline melanoma biopsies from patients with advanced melanoma who received either anti-PD-1 mono-therapy or a combination with anti-CTLA-4. Particularly, FcyRIIIa (CD16)-expressing macrophage densities were inves-tigated for associations with response and progression-free survival.Experimental Design: Patients with advanced melanoma who received either anti-PD-1 monotherapy or combination anti-PD-1 and anti-CTLA-4 were retrospectively identified. Macrophage populations were analyzed within baseline melanoma biopsies via multiplex IHC in relation to treatment outcomes.Results: Patients who responded to combination immune checkpoint inhibitor contained higher CD16 & PLUSMN; macrophage densities than those who did not respond (196 vs. 7 cells/mm2; P = 0.0041). There was no diffidence in CD16 & PLUSMN; macrophage densities in the PD-1 monotherapy-treated patients based on response (118 vs. 89 cells/mm2; P = 0.29). A significantly longer 3-year progression-free survival was observed in combination-treated patients with high intratumoral densities of CD16 & PLUSMN; macrophages compared with those with low densities (87% vs. 42%, P = 0.0056, n = 40). No association was observed in anti-PD-1 monotherapy-treated patients (50% vs. 47%, P = 0.4636, n = 50). Melanoma biopsies with high densities of CD16 & PLUSMN; macrophages contained upregulated gene expression of critical T-cell recruiting chemokines (CXCL9, CXCL10, and CXCL11). Conclusions: Our data demonstrate that tumor microenviron-ments enriched with CD16 & PLUSMN; macrophages are favorable for response to combination anti-PD-1 and anti-CTLA-4 therapy but not anti-PD-1 monotherapy. These data provides a potential biomarker of response for combination immunotherapies in patients with metastatic melanoma. See related commentary by Smithy and Luke, p. 2345

引用

页码：2513 / 2524

页数：12

共 50 条

[1] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
Reddy, Swathi B.
Possick, Jennifer D.
Kluger, Harriet M.
Galan, Anjela
Han, Dale
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
[2] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
Rogiers, Aljosja
Dimitriou, Florentia
Lobon, Irene
Harvey, Catriona
Vergara, Ismael A.
da Silva, Ines Pires
Lo, Serigne N.
Scolyer, Richard A.
Carlino, Matteo S.
Menzies, Alexander M.
Long, Georgina V.
EUROPEAN JOURNAL OF CANCER, 2024, 198
[3] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
Robert, Caroline
Mateus, Christina
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
[4] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Afzal, Muhammad Zubair
Mabaera, Rodwell
Shirai, Keisuke
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[5] NEOADJUVANT ANTI-PD-1 AND ANTI-CTLA-4 COMBINATION THERAPY INDUCED INTRATUMORAL IMMUNOLOGIC ALTERATIONS IN RECURRENT GBM PATIENTS
Markus, Lauren
Wen, Patrick
Sun, Lu
Hugo, Willy
Prins, Robert
NEURO-ONCOLOGY, 2024, 26
[6] Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
da Silva, Ines Pires
Li, Isabel
Ugurel, Selma
Serra-Bellver, Patricio
Andhale, Avanti
Burnette, Hannah
Aya, Francisco
Conway, Jordan W.
Braden, Jorja
Carlino, Matteo S.
Menzies, Alexander M.
Weichenthal, Michael
Mohr, Peter
Gutzmer, Ralf
Arance, Ana M.
Johnson, Douglas B.
Lorigan, Paul
Schadendorf, Dirk
Lo, Serigne N.
Long, Georgina V.
EUROPEAN JOURNAL OF CANCER, 2024, 205
[7] Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
Gide, Tuba Nur
Quek, Camelia
Madore, Jason
Menzies, Alexander M.
Dent, Rebecca
Carlino, Matteo S.
Guminski, Alex
Saw, Robyn
Thompson, John F.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
[8] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Ellebaek, Eva
Khan, Shawez
Bastholt, Lars
Schmidt, Henrik
Haslund, Charlotte Aaquist
Donia, Marco
Svane, Inge Marie
EUROPEAN JOURNAL OF CANCER, 2024, 198
[9] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Afzal, Muhammad Zubair
Mercado, Rima R.
Shirai, Keisuke
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[10] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S.
Prithviraj, P.
Lorigan, P.
Larkin, J.
McArthur, G.
Atkinson, V.
Millward, M.
Khou, M.
Diem, S.
Ramanujam, S.
Kong, B.
Liniker, E.
Guminski, A.
Parente, P.
Andrews, M. C.
Parakh, S.
Cebon, J.
Long, G. V.
Carlino, M. S.
Klein, O.
BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089

← 1 2 3 4 5 →